Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma - Regional Cancer Care Associates LLC

Clinical Trials

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue
Locations
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA6141
Cancer Diagnosis
To Learn More Call
201-510-0910